NEW YORK (GenomeWeb News) – Response Biomedical today reported that product sales for the first quarter rose 50 percent year over year on the strength of its cardiovascular tests.

The Vancouver, British Columbia-based firm recorded product sales of C$3 million (US$3 million) for the three months ended March 31, up from $2 million a year ago, as cardiovascular sales increased 80 percent year over year to $2.7 million from $1.5 million. Improved performance in China was the primary driver of growth in the cardiovascular business, Response Biomedical said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.